PURE Bioscience, Inc.
corporate_fare Company Profile
PURE Bioscience, Inc. (OTC:PURE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for PURE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for PURE spans 10-K, 8-K, 10-Q.
Recent high-impact activity:
- PURE Bioscience 10-K: Auditors Flag Going Concern as Cash Falls to $569,000
- PURE Bioscience FY2026: Sales Up 5% to $2.32M, Net Loss Widens to $2.48M, $1.0M of Related-Party Notes Past Due
- Pure Bioscience Raises $555K in Private Placement; Director Lee Funds Entire Round
- PURE Bioscience Q3 Net Loss Widens to $624K on $506K Revenue
- PURE Bioscience Reports Increased Q3 Loss, Raises $1M in Dilutive Private Placement, and Authorizes 92% More Shares
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,982 shares in PURE as of the October 30, 2026 settlement, a 54.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 1.9% of PURE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for PURE, detected from its recent SEC filings · based on capital-structure filings through 2026-10-20.
Related-Party Private Placement Closes · Pricing Below Current Market
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →